Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20344)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Primary Target | Pathway | GR50 | GRmax | GR_AOC | Death_AUC | GR Hill Coefficient | GEC50 | GR r2 |
---|---|---|---|---|---|---|---|---|---|---|
PDX1258 | Buparlisib | pan PI3K | PI3K/mTOR | 1.3631 | -0.3924 | 0.2516 | 0.0862 | 1.2064 | 2.8058 | 0.99443 |
MCF 10A | Buparlisib | pan PI3K | PI3K/mTOR | 1.465 | -0.1604 | 0.2493 | 0.0444 | 1.6479 | 1.8654 | 0.99356 |
HCC1500 | Buparlisib | pan PI3K | PI3K/mTOR | 0.20179 | -0.5459 | 0.5351 | 0.1146 | 0.8962 | 0.51424 | 0.99364 |
SUM1315MO2 | Buparlisib | pan PI3K | PI3K/mTOR | 0.40124 | -0.3686 | 0.4388 | 0.1149 | 0.9148 | 0.94031 | 0.98014 |
CAL-85-1 | Buparlisib | pan PI3K | PI3K/mTOR | 0.34255 | -0.3199 | 0.4420 | 0.1137 | 0.9213 | 0.69609 | 0.99686 |
MDA-MB-436 | Buparlisib | pan PI3K | PI3K/mTOR | 1.1815 | -0.2866 | 0.2925 | 0.0578 | 1.6196 | 1.6556 | 0.99244 |
Hs 578T | Buparlisib | pan PI3K | PI3K/mTOR | 0.68631 | -0.3434 | 0.3760 | 0.1520 | 1.4596 | 1.0562 | 0.9918 |
HME1 | Buparlisib | pan PI3K | PI3K/mTOR | 1.1504 | -0.2416 | 0.2469 | 0.0826 | 1.9615 | 1.4311 | 0.99598 |
SUM149PT | Buparlisib | pan PI3K | PI3K/mTOR | 1.4121 | -0.3357 | 0.2539 | 0.1216 | 1.9093 | 1.9133 | 0.99941 |
MDA-MB-231 | Buparlisib | pan PI3K | PI3K/mTOR | 1.5103 | -0.2351 | 0.2751 | 0.0596 | 1.9855 | 1.8969 | 0.98328 |
BT-549 | Buparlisib | pan PI3K | PI3K/mTOR | 1.419 | -0.2716 | 0.2487 | 0.0802 | 2.0178 | 1.8107 | 0.99484 |
MDA-MB-361 | Buparlisib | pan PI3K | PI3K/mTOR | 0.21797 | -0.9584 | 0.6114 | 0.1763 | 0.9709 | 0.67584 | 0.99384 |
MDA-MB-134-VI | Buparlisib | pan PI3K | PI3K/mTOR | 0.15425 | -0.8251 | 0.6432 | 0.1617 | 0.9833 | 0.45209 | 0.98862 |
HCC1419 | Buparlisib | pan PI3K | PI3K/mTOR | 0.39623 | -0.4961 | 0.4499 | 0.0745 | 0.8204 | 1.2651 | 0.99188 |
HCC1428 | Buparlisib | pan PI3K | PI3K/mTOR | 0.69074 | -0.2646 | 0.3524 | 0.1087 | 1.9122 | 0.88637 | 0.99206 |
MDA-MB-468 | Buparlisib | pan PI3K | PI3K/mTOR | 0.83168 | -0.5157 | 0.3573 | 0.2010 | 2.1267 | 1.1738 | 0.99824 |
PDXHCI002 | Buparlisib | pan PI3K | PI3K/mTOR | 1.4379 | -0.4797 | 0.2447 | 0.1228 | 3.2385 | 1.7721 | 0.99509 |
MDA-MB-453 | Buparlisib | pan PI3K | PI3K/mTOR | 0.69073 | -0.6073 | 0.3442 | 0.1124 | 1.2215 | 1.4247 | 0.9883 |
HCC1937 | Buparlisib | pan PI3K | PI3K/mTOR | 1.4479 | -0.2256 | 0.2634 | 0.0691 | 1.0878 | 2.8639 | 0.99474 |
MCF7 | Buparlisib | pan PI3K | PI3K/mTOR | 0.18746 | -0.2690 | 0.5035 | 0.1162 | 0.8936 | 0.34198 | 0.99189 |
CAMA-1 | Cabozantinib | VEGFR2/MET | RTK | 8.7107 | 0.2436 | 0.0342 | 0.0090 | 4.9963 | 10.1282 | 0.97965 |
SUM149PT | Cabozantinib | VEGFR2/MET | RTK | 5.7589 | 0.2895 | 0.0383 | 0.0198 | 4.7896 | 4.9143 | 0.99303 |
PDXHCI002 | Cabozantinib | VEGFR2/MET | RTK | 7.2097 | 0.2341 | 0.0443 | 0.0248 | 1.8969 | 12.8614 | 0.98302 |
HCC1954 | Cabozantinib | VEGFR2/MET | RTK | 10.9106 | 0.6390 | -0.0135 | -0.0074 | 5.0000 | 13.0234 | 0.87916 |
BT-20 | Cabozantinib | VEGFR2/MET | RTK | 5.3516 | -0.2030 | 0.0566 | 0.0432 | 4.9846 | 5.8613 | 0.99079 |